Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
22 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
GliaCure Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'GliaCure Inc. - Product Pipeline Review - 2015', provides an overview of the GliaCure Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of GliaCure Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of GliaCure Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of GliaCure Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the GliaCure Inc.'s pipeline products Reasons to buy - Evaluate GliaCure Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of GliaCure Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the GliaCure Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of GliaCure Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of GliaCure Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of GliaCure Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 GliaCure Inc. Snapshot 4 GliaCure Inc. Overview 4 Key Information 4 Key Facts 4 GliaCure Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 GliaCure Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 GliaCure Inc. - Pipeline Products Glance 9 GliaCure Inc. - Clinical Stage Pipeline Products 9 Phase I Products/Combination Treatment Modalities 9 GliaCure Inc. - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Discovery Products/Combination Treatment Modalities 11 GliaCure Inc. - Drug Profiles 12 GC-021109 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 Drug for Depression 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Drug for CNS Disorders 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 GliaCure Inc. - Pipeline Analysis 15 GliaCure Inc. - Pipeline Products by Target 15 GliaCure Inc. - Pipeline Products by Route of Administration 16 GliaCure Inc. - Pipeline Products by Molecule Type 17 GliaCure Inc. - Pipeline Products by Mechanism of Action 18 GliaCure Inc. - Recent Pipeline Updates 19 GliaCure Inc. - Locations And Subsidiaries 20 Head Office 20 Appendix 21 Methodology 21 Coverage 21 Secondary Research 21 Primary Research 21 Expert Panel Validation 21 Contact Us 21 Disclaimer 22
List of Tables
GliaCure Inc., Key Information 4 GliaCure Inc., Key Facts 4 GliaCure Inc. - Pipeline by Indication, 2015 6 GliaCure Inc. - Pipeline by Stage of Development, 2015 7 GliaCure Inc. - Monotherapy Products in Pipeline, 2015 8 GliaCure Inc. - Phase I, 2015 9 GliaCure Inc. - Preclinical, 2015 10 GliaCure Inc. - Discovery, 2015 11 GliaCure Inc. - Pipeline by Target, 2015 15 GliaCure Inc. - Pipeline by Route of Administration, 2015 16 GliaCure Inc. - Pipeline by Molecule Type, 2015 17 GliaCure Inc. - Pipeline Products by Mechanism of Action, 2015 18 GliaCure Inc. - Recent Pipeline Updates, 2015 19
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.